Abstract
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by high level of megakaryocyte and platelet count.In recent years,the discovery of Janus kinase (JAK)2 V617F mutation has revolutionized the pathogenesis and diagnosis of ET.The mutation of thrombopoietin receptor (MPL),cell-cycle checkpoint kinase (CHEK)2,ten eleven translocation (TET)2,calreticulin (CALR) and other genes replenishes pathogenesis of ET.Traditional therapy which used hydroxyurea or interferon can reduce platelet count of ET patient,and drugs such as aspirin or anagrelide were able to interfere the function of platelet.What's more,breakthrough of ET therapy has been made in a number of clinical trials of JAK2 inhibitors.This article reviews the literatures on the pathogenesis,diagnosis,risk factor and therapy of ET. Key words: Thrombocythemia, essential; Etiology; Diagnosis; Drug therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
